% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Turco:299496,
      author       = {F. Turco and S. Gillessen and K. Herrmann$^*$ and G. Paone
                      and A. Omlin},
      title        = {{T}reatment {L}andscape of {P}rostate {C}ancer in the {E}ra
                      of {PSMA} {R}adiopharmaceutical {T}herapy.},
      journal      = {Journal of nuclear medicine},
      volume       = {66},
      number       = {5},
      issn         = {0097-9058},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {DKFZ-2025-00455},
      pages        = {665-672},
      year         = {2025},
      note         = {2025 May 1;66(5):665-672},
      abstract     = {The treatment landscape of prostate cancer is quite complex
                      because of the many therapeutic options available in
                      different disease settings (hormonal treatments,
                      chemotherapy, poly(adenosine diphosphate ribose) polymerase
                      inhibitors, radiopharmaceutical therapy). Since in most
                      cases we do not have comparative studies between these
                      different agents, the best therapeutic sequence in patients
                      with prostate cancer remains unsolved. In this review, we
                      describe the different systemic therapeutic options
                      available in each disease setting from localized disease to
                      metastatic castration-resistant disease. We also indicate
                      when to use each of these therapeutic options in the
                      therapeutic sequence on the basis of the results of the
                      available studies. A special focus of this review is the
                      place of prostate-specific membrane antigen
                      radiopharmaceutical therapy in the treatment algorithms.},
      subtyp        = {Review Article},
      keywords     = {advanced prostate cancer (Other) / mCRPC (Other) / mHSPC
                      (Other) / radiopharmaceutical therapy (Other) /
                      radiopharmaceuticals (Other) / systemic therapies (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40015917},
      doi          = {10.2967/jnumed.124.267730},
      url          = {https://inrepo02.dkfz.de/record/299496},
}